期刊文献+

心房颤动的抗栓与抗血小板治疗 被引量:2

原文传递
导出
摘要 目的:了解临床实践中心房颤动(房颤)患者抗栓治疗的现状及分析。方法:调查2003年(225例) -2004年(280例)年间有血栓栓塞高危因素的房颤患者接受抗栓治疗的情况。结果:发现2年间高危因素有明显增加(由平均1.4个增加到1.8个),但接受抗栓治疗均以阿司匹林为主(64.8%与72.5%),服用华法林的比例很低(4.0%与6.25%),且剂量均偏低。结论:临床实践中房颤接受抗栓治疗达到标准的比例很低,接受阿司匹林治疗者较多,但剂量偏少,接受华法林治疗者很少,房颤的抗栓治疗尚需进一步规范。
作者 周方 傅国胜
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2006年第5期311-312,共2页 Journal of Clinical Cardiology
  • 相关文献

参考文献2

二级参考文献3

  • 1Pengo V, de Caterina R. Prevention of thromboembolism in non-rheumatic atrial fibrillation: An update. Ital Heart J,2001, 2(9 Suppl) :972-979.
  • 2Taylor F C, Cohen H, Ebrahim S. Systematic review of long term anticoagulation or antiplatelet treatment in patients with nonrheumatic atrial fibrillation. BMJ,2001, 322: 321--326.
  • 3Koudstaal P J. Anticoagulants versus antiplatelet therapy for preventing stroke in patients With nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks. Cochrane Database Syst Rev, 2000,CD000187-- CD000187.

共引文献24

同被引文献23

  • 1International Stroke Trial Collaborative Group. The International Strok Trial (IST) : a randomized trial of aspirin, subcutaneous heparin, both, or, neither among 19 435 patients with acute ischemic stroke [J]. Lancet. 1997.349,1569-1581.
  • 2CAST (Chinese Acute Stroke Trial ) Collaboration Group. CAST: randomized placebo-controlled trial of early aspirin use in 20000 patients with acute ischemic stroke [ J ]. Lancet, 1997,349 : 1641-1649.
  • 3Halperin JL. SPORTIF Ⅲ and V study Investigators Eifficacy and safety of oral direct thrombin inhibitor ximeiagatran compared with dose-adjusted warfarin in the prevention of stroke and systemic embolic events in patients with atrial fibrillation ( SPORTIF V ). AHA Plenary Session Ⅶ.
  • 4Sacco RL, Elkind MS. Update on antiplatelet therapy for stroke prevention[ J ]. Arch Intern Med ,2000,160 : 1579-1582.
  • 5Kannel WB, wolf PA, Benjamin EJ, et al. Prevalence,incidence prognosis and predisposing conditions for atrial fibrillation: population based estimates [ J ] Am J Cardiol, 1998, 82:2N-9N.
  • 6Corrado G, Tadeo G, Beretta S, et al. Atrial thromb: resolution after prolonged anticoagnlation in patients with atrial fibrillation [J] chest, 1999 ; 115 ( 1 ) : 140-143.
  • 7Li S, Hee FL, Blann AD, et al. Effect soffixedlow dose warfarin, aspirin warfarin combination therapy and dose adjusted warfarin on thrombogenesis in chronic artrial frbtrillation [J] Stroke ,2000 ;31 (4) :828-833.
  • 8Olsson SB. Executive Steering Committee on behalf of the SPORTIF Ⅲ Investigators stroke prevention with the oral direct thrombin inhibitor SPORTIF Ⅱ investigators fibrillation (SPORTIF Ⅲ):random ised controlled trial [ J]. Chest, 2003,362 : 1691-1698.
  • 9Ezekowitz MD, Relily P, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study) [ J ]. Am J Cardiol,2007,100 ( 9 ) : 1419-1426.
  • 10Turpie AG, Gent K, Bauer K, et al. Evaluation of the factorXa (FXa) inhibitor, PRT054021 (PRT021), against enoxaparin in a randomized trial for the prevention of venous thromboembolie events after total knee replacement (EXPERT) [ J ]. J Thromb Haemost ,2007 ,5 ( Snppl 2).

引证文献2

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部